NanoVibronix Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.491
- Today's High:
- $2.85
- Open Price:
- $2.54
- 52W Low:
- $1.41
- 52W High:
- $12.9
- Prev. Close:
- $2.58
- Volume:
- 91741
Company Statistics
- Market Cap.:
- $11.79 million
- Book Value:
- 0.701
- Revenue TTM:
- $643000
- Operating Margin TTM:
- -690.37%
- Gross Profit TTM:
- $167000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -53.49%
- Return on Equity TTM:
- -195.7%
Company Profile
NanoVibronix Inc had its IPO on 2017-06-27 under the ticker symbol NAOV.
The company operates in the Healthcare sector and Medical Devices industry. NanoVibronix Inc has a staff strength of 9 employees.
Stock update
Shares of NanoVibronix Inc opened at $2.54 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.49 - $2.85, and closed at $2.85.
This is a +10.47% increase from the previous day's closing price.
A total volume of 91,741 shares were traded at the close of the day’s session.
In the last one week, shares of NanoVibronix Inc have increased by +11.33%.
NanoVibronix Inc's Key Ratios
NanoVibronix Inc has a market cap of $11.79 million, indicating a price to book ratio of 3.7176 and a price to sales ratio of 6.4388.
In the last 12-months NanoVibronix Inc’s revenue was $643000 with a gross profit of $167000 and an EBITDA of $-4438092. The EBITDA ratio measures NanoVibronix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, NanoVibronix Inc’s operating margin was -690.37% while its return on assets stood at -53.49% with a return of equity of -195.7%.
In Q2, NanoVibronix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 39.4%.
NanoVibronix Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-3.2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into NanoVibronix Inc’s profitability.
NanoVibronix Inc stock is trading at a EV to sales ratio of 6.0044 and a EV to EBITDA ratio of -1.6691. Its price to sales ratio in the trailing 12-months stood at 6.4388.
NanoVibronix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.83 million
- Total Liabilities
- $2.37 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
NanoVibronix Inc ended 2024 with $3.83 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.83 million while shareholder equity stood at $1.17 million.
NanoVibronix Inc ended 2024 with $0 in deferred long-term liabilities, $2.37 million in other current liabilities, 2000.00 in common stock, $-64556000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $253000.00 and cash and short-term investments were $253000.00. The company’s total short-term debt was $37,000 while long-term debt stood at $0.
NanoVibronix Inc’s total current assets stands at $3.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $247000.00 compared to accounts payable of $33000.00 and inventory worth $3.11 million.
In 2024, NanoVibronix Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, NanoVibronix Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.85
- 52-Week High
- $12.9
- 52-Week Low
- $1.41
- Analyst Target Price
- $
NanoVibronix Inc stock is currently trading at $2.85 per share. It touched a 52-week high of $12.9 and a 52-week low of $12.9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.78 and 200-day moving average was $4.21 The short ratio stood at 7.2 indicating a short percent outstanding of 0%.
Around 62.4% of the company’s stock are held by insiders while 357.7% are held by institutions.
Frequently Asked Questions About NanoVibronix Inc
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.